Eisai Executive and Leadership Team

Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching research and development pipeline for neurological and oncological therapies. By overseeing the integration of scientific discovery with commercial strategy, the President & Chief Executive Officer & Scientific Chief & Officer ensures that pharmaceutical breakthroughs reach patients suffering from Alzheimer's disease and various cancers. This leadership role involves constant collaboration with global research teams to refine the efficacy of products like Aricept and Lenvima. Toshio Imai maintains rigorous standards for clinical trials while driving the long-term vision for the company's therapeutic portfolio. Through the alignment of scientific innovation with market demands, the President & Chief Executive Officer & Scientific Chief & Officer secures the competitive position of the organization within the global pharmaceutical landscape, ultimately fostering sustainable growth and improved patient outcomes across diverse international markets.

Shaji Procida, the President & Chief Operating Officer at Eisai, manages the daily execution of pharmaceutical manufacturing and supply chain logistics. Overseeing the production of essential medications like Methycobal and Fycompa, the President & Chief Operating Officer ensures that manufacturing facilities maintain strict quality control and regulatory compliance. This leadership role requires constant coordination with internal departments to optimize operational efficiency and reduce overhead costs. Shaji Procida drives the implementation of advanced manufacturing technologies to support the broad distribution of products across the Japanese market and beyond. By streamlining the path from production to patient access, the President & Chief Operating Officer directly impacts the availability of critical treatments for peripheral neuropathy and epilepsy. Through meticulous oversight of operational workflows, Procida guarantees that the company meets its production targets while upholding the highest standards of safety and reliability in the pharmaceutical industry.

Cynthia Schwalm, the President at Eisai, leads the strategic expansion of the company's commercial footprint and market penetration. Overseeing the marketing and sales initiatives for products like Dayvigo and Halaven, the President ensures that healthcare providers receive accurate information regarding therapeutic applications. This leadership role involves building strong relationships with medical institutions and regulatory bodies to facilitate the adoption of new treatments. Cynthia Schwalm drives the development of regional market strategies that align with the company's mission to improve patient quality of life. By analyzing market trends and competitive dynamics, the President identifies opportunities for growth in the autoimmune and oncology sectors. Through the coordination of cross-functional teams, Schwalm optimizes the commercialization process for diverse pharmaceutical offerings. This focus on strategic market engagement ensures that the organization remains a leader in providing effective solutions for insomnia and complex autoimmune conditions.

Michael De, the President, Eisai Machinery (USA) at Eisai, directs the specialized operations of the machinery division focused on pharmaceutical manufacturing equipment. Overseeing the engineering and technical support teams, the President, Eisai Machinery (USA) ensures that the hardware used in drug production meets the precise requirements of the pharmaceutical industry. This leadership role involves managing the development of advanced machinery that supports the creation of high-quality tablets and capsules. Michael De drives the expansion of the machinery division's reach within the North American market, providing essential infrastructure for pharmaceutical manufacturing. By fostering innovation in equipment design, the President, Eisai Machinery (USA) enhances the efficiency and precision of the production process for various medications. Through the strategic management of technical resources and client partnerships, De supports the broader organizational goal of delivering reliable and effective pharmaceutical products to patients worldwide.